Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study

Lin, E; Garmo, Hans; Hemelrijck, Mieke Van; Adolfsson, Jan; Stattin, Pär; Zethelius, Björn; Crawley, Danielle

doi:10.1186/s12885-020-07036-4

Cited by 16 publications

(13 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In humans, there is an inverse association between diabetes mellitus (or metabolic syndrome) and PCa [ 118 119 ], which has been shown in studies conducted mainly in the white people [ 120 121 122 ]. However, in Taiwan we demonstrated that diabetes patients have a significantly higher incidence of [ 123 ] and mortality from [ 124 ] PCa.…”

Section: Prostate-related Healthmentioning

confidence: 99%

The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review

Tseng

2022

World J Mens Health

View full text Add to dashboard Cite

Metformin is the first-line oral antidiabetic drug that shows multiple pleiotropic effects of anti-inflamation, anti-cancer, anti-aging, anti-microbia, anti-atherosclerosis, and immune modulation. Metformin's effects on men's related health are reviewed here, focusing on reproductive health under subtitles of erectile dysfunction (ED), steroidogenesis and spermatogenesis; and on prostate-related health under subtitles of prostate specific antigen (PSA), prostatitis, benign prostate hyperplasia (BPH), and prostate cancer (PCa). Updated literature suggests a potential role of metformin on arteriogenic ED but controversial and contradictory effects (either protective or harmful) on testicular functions of testosterone synthesis and spermatogenesis. With regards to prostate-related health, metformin use may be associated with lower levels of PSA in humans, but its clinical implications require more research. Although there is a lack of research on metform's effect on prostatitis, it may have potential benefits through its anti-microbial and anti-inflammatory properties. Metformin may reduce the risk of BPH by inhibiting the insulin-like growth factor 1 pathway and some but not all studies suggest a protective role of metformin on the risk of PCa. Many clinical trials are being conducted to investigate the use of metformin as an adjuvant therapy for PCa but results currently available are not conclusive. While some trials suggest a benefit in reducing the metastasis and recurrence of PCa, others do not show any benefit. More research works are warranted to illuminate the potential usefulness of metformin in the promotion of men's health.

show abstract

Section: Prostate-related Healthmentioning

confidence: 99%

The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review

Tseng

2022

World J Mens Health

View full text Add to dashboard Cite

show abstract

“…So, its forceful activation to express can be a potential therapeutic approach[ 43 ]. Therefore, both metformin and certain therapies help in blocking cell cycle progression by reducing mTOR activity[ 44 ]. Hypogonadism (decrease in level of testosterone) is also found associated with both diabetes and prostate cancer (PCa).…”

Section: Prostate Cancer and Diabetes Linco1128mentioning

confidence: 99%

Diabetes mellitus susceptibility with varied diseased phenotypes and its comparison with phenome interactome networks

Rout¹,

Kour²,

Vuree³

et al. 2022

WJCC

View full text Add to dashboard Cite

An emerging area of interest in understanding disease phenotypes is systems genomics. Complex diseases such as diabetes have played an important role towards understanding the susceptible genes and mutations. A wide number of methods have been employed and strategies such as polygenic risk score and allele frequencies have been useful, but understanding the candidate genes harboring those mutations is an unmet goal. In this perspective, using systems genomic approaches, we highlight the application of phenome-interactome networks in diabetes and provide deep insights. LINC01128, which we previously described as candidate for diabetes, is shown as an example to discuss the approach.

show abstract

“…The scope of such studies is extremely broad owing to the range of datasets currently included. To date, most studies have investigated risks associated with other comorbid diseases (e.g., diabetes [ 27 ]) or specific medications (e.g., 5-apha reductase inhibitors for benign hyperplasia [ 28 ], testosterone replacement therapy [ 29 ], anti-inflammatory medications [ 30 ], antidiabetic medications [ 31 ] and the antihypertensive drug spironolactone, known to have antiandrogenic effects [ 32 ]). In addition, case–control studies using PCBaSe have also examined immigrant status [ 33 ], fatherhood status [ 34 , 35 ] and family history of PCa [ 36 ].…”

Section: The Value Of Rwd In Understanding Pca—examples From Swedimentioning

confidence: 99%

The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish Registries

Beckmann

Garmo

Lissbrant

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Real-world data (RWD), that is, data from sources other than controlled clinical trials, play an increasingly important role in medical research. The development of quality clinical registers, increasing access to administrative data sources, growing computing power and data linkage capacities have contributed to greater availability of RWD. Evidence derived from RWD increases our understanding of prostate cancer (PCa) aetiology, natural history and effective management. While randomised controlled trials offer the best level of evidence for establishing the efficacy of medical interventions and making causal inferences, studies using RWD offer complementary evidence about the effectiveness, long-term outcomes and safety of interventions in real-world settings. RWD provide the only means of addressing questions about risk factors and exposures that cannot be “controlled”, or when assessing rare outcomes. This review provides examples of the value of RWD for generating evidence about PCa, focusing on studies using data from a quality clinical register, namely the National Prostate Cancer Register (NPCR) Sweden, with longitudinal data on advanced PCa in Patient-overview Prostate Cancer (PPC) and data linkages to other sources in Prostate Cancer data Base Sweden (PCBaSe).

show abstract

Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study

Cited by 16 publications

References 43 publications

The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review

The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review

Diabetes mellitus susceptibility with varied diseased phenotypes and its comparison with phenome interactome networks

The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish Registries

Contact Info

Product

Resources

About